Novel anti-angiogenic PEDF-derived small peptides mitigate choroidal neovascularization. (November 2019)

• Record Type: Journal Article
• Authors: Sheibani, Nader; Wang, Shoujian; Darjatmoko, Soesiawati R.; Fisk, Debra L.; Shahi, Pawan K.; Pattnaik, Bikash R.; Sorenson, Christine M.; Bhowmick, Reshma; Volpert, Olga V.; Albert, Daniel M.; Melgar-Asensio, Ignacio; Henkin, Jack
• Is Part Of: Experimental eye research. Volume 188(2019)
• Publication Date: 2019-11
• Subjects: Angiogenesis -- PEDF -- Choroidal neovascularization -- Peptides -- Retinopathy -- Macular degeneration -- Laminin receptor -- YIGSR; Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2019.107798
• Languages: English
• ISSNs: 0014-4835

Abstract

Abstract: Abnormal migration and proliferation of endothelial cells (EC) drive neovascular retinopathies. While anti-VEGF treatment slows progression, pathology is often supported by decrease in intraocular pigment epithelium-derived factor (PEDF), an endogenous inhibitor of angiogenesis. A surface helical 34-mer peptide of PEDF, comprising this activity, is efficacious in animal models of neovascular retina disease but remains impractically large for therapeutic use. We sought smaller fragments within this sequence that mitigate choroidal neovascularization (CNV). Expecting rapid intravitreal (IVT) clearance, we also developed a method to reversibly attach peptides to nano-carriers for extended delivery. Synthetic fragments of 34-mer yielded smaller anti-angiogenic peptides, and N-terminal capping with dicarboxylic acids did not diminish activity. Charge restoration via substitution of an internal aspartate by asparagine improved potency, achieving low nM apoptotic response in VEGF-activated EC. Two optimized peptides (PEDF 335, 8-mer and PEDF 336, 9-mer) were tested in a mouse model of laser-induced CNV. IVT injection of either peptide, 2–5 days before laser treatment, gave significant CNV decrease at day +14 post laser treatment. The 8-mer also decreased CNV, when administered as eye drops. Also examined was a nanoparticle-conjugate (NPC) prodrug of the 9-mer, having positive zeta potential, expected to display longer intraocular residence. This NPC showed extended efficacy, even when injected 14 days before laser treatment. Neither inflammatory cells nor other histopathologic abnormalities were seen in rabbit eyes harvested 14 days following IVT injection of PEDF 336 (>200 μg). No rabbit or mouse eye irritation was observed over 12–17 days of PEDF 335 eye drops (10 mM). Viability was unaffected in 3 retinal and 2 choroidal cell types by PEDF 335 up to 100 μM, PEDF 336 (100 μM) gave slight growth inhibition only in choroidal EC. A small anti-angiogenic PEDF epitope (G-Y -D -L-Y-R-V ) was identified, variants (adipic-Sar-Y -N -L-Y-R-V ) mitigate CNV, with clinical potential in treating neovascular retinopathy. Their shared active motif, Y - - - R, is found in laminin (Ln) peptide YIGSR, which binds Ln receptor 67LR, a known high-affinity ligand of PEDF 34-mer. Highlights: 18 to 34-mer peptides from PEDF are potently anti-angiogenic but impractically large for therapeutic use. Modified 8 to 9-mer subfragments were discovered to induce EC apoptosis and inhibit CNV via intravitreal injection. Anti-VEGF combination is not beneficial, 8-mer eye drops inhibited CNV, implies use in corneal neovascularization. Poly-cationic nanoparticle conjugate of 9-mer shows extended CNV protection.